243 related articles for article (PubMed ID: 35527989)
1. Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease.
Wu HHL; Chinnadurai R
Kidney Dis (Basel); 2022 Mar; 8(2):103-114. PubMed ID: 35527989
[TBL] [Abstract][Full Text] [Related]
2. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
4. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
Luo J; Jensen DE; Maroni BJ; Brunelli SM
Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
[TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agent hyporesponsiveness.
Johnson DW; Pollock CA; Macdougall IC
Nephrology (Carlton); 2007 Aug; 12(4):321-30. PubMed ID: 17635745
[TBL] [Abstract][Full Text] [Related]
6. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
7. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
[TBL] [Abstract][Full Text] [Related]
8. Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.
Gillespie IA; Macdougall IC; Richards S; Jones V; Marcelli D; Froissart M; Eckardt KU;
Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):414-26. PubMed ID: 25690434
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Ogawa T; Nitta K
Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
[TBL] [Abstract][Full Text] [Related]
10. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
[TBL] [Abstract][Full Text] [Related]
11. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Inflammation on Anemia in CKD Patients.
Gluba-Brzózka A; Franczyk B; Olszewski R; Rysz J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979104
[TBL] [Abstract][Full Text] [Related]
13. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China.
Sui Z; Wang M; Zuo L
Medicine (Baltimore); 2019 Jan; 98(2):e13981. PubMed ID: 30633179
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
[TBL] [Abstract][Full Text] [Related]
15. [Pathogenesis and treatment of anemia in chronic kidney disease].
Nangaku M
Rinsho Ketsueki; 2017; 58(10):1860-1863. PubMed ID: 28978825
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era.
Cizman B; Smith HT; Camejo RR; Casillas L; Dhillon H; Mu F; Wu E; Xie J; Zuckerman P; Coyne D
Kidney Med; 2020; 2(5):589-599.e1. PubMed ID: 33089137
[TBL] [Abstract][Full Text] [Related]
17. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.
Icardi A; Paoletti E; De Nicola L; Mazzaferro S; Russo R; Cozzolino M
Nephrol Dial Transplant; 2013 Jul; 28(7):1672-9. PubMed ID: 23468534
[TBL] [Abstract][Full Text] [Related]
18. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Karaboyas A; Morgenstern H; Fleischer NL; Vanholder RC; Dhalwani NN; Schaeffner E; Schaubel DE; Akizawa T; James G; Sinsakul MV; Pisoni RL; Robinson BM
Kidney Med; 2020; 2(3):286-296. PubMed ID: 32734248
[TBL] [Abstract][Full Text] [Related]
19. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
[TBL] [Abstract][Full Text] [Related]
20. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.
Usui T; Zhao J; Fuller DS; Hanafusa N; Hasegawa T; Fujino H; Nomura T; Zee J; Young E; Robinson BM; Nangaku M
Nephrology (Carlton); 2021 Jan; 26(1):46-53. PubMed ID: 32743932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
